세계의 혈관내피세포성장인자(VEGF) 저해제 시장 : COVID-19의 영향 분석 - 약제 유형별, 투여 경로별, 용도별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market with COVID-19 Impact Analysis, By Drug Type, By Route of Administration, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

US $ 3,250 ￦ 4,702,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,728,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 8,174,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 혈관내피세포성장인자(VEGF) 저해제 시장 규모는 2022년에 89억 70만 달러에 달하고, 2023-2030년에 CAGR로 9.1%의 성장이 예측됩니다.

세계의 혈관내피세포성장인자(VEGF) 저해제 시장에 대해 조사분석했으며, 시장 동향, 지역과 부문 분석, 기업 개요 등을 제공하고 있습니다.

목차

제1장 혈관내피세포성장인자(VEGF) 저해제 시장의 개요

제2장 주요 요약

제3장 혈관내피세포성장인자(VEGF) 저해제의 주요 시장 동향

• 혈관내피세포성장인자(VEGF) 저해제 시장 촉진요인
  • 시장 촉진요인의 영향 분석
• 혈관내피세포성장인자(VEGF) 저해제 시장 억제요인
  • 시장 억제요인의 영향 분석
• 혈관내피세포성장인자(VEGF) 저해제 시장의 기회
• 혈관내피세포성장인자(VEGF) 저해제 시장의 미래 동향

제4장 혈관내피세포성장인자(VEGF) 저해제 업계의 조사

• PEST 분석
• Porter's Five Forces 분석
• 성장 전망 매핑
• 규제 구조 분석

제5장 혈관내피세포성장인자(VEGF) 저해제 시장 : COVID-19의 영향 분석

• COVID-19 이전의 영향 분석
• COVID-19 이후의 영향 분석

제6장 혈관내피세포성장인자(VEGF) 저해제 시장 구도

• 혈관내피세포성장인자(VEGF) 저해제 시장 점유율 분석(2022년)
• 내역 데이터 : 주요 제조업체별
  • 기존 기업의 분석
  • 신규 기업 분석

제7장 혈관내피세포성장인자(VEGF) 저해제 시장 - 약제 유형별

• 개요

제8장 혈관내피세포성장인자(VEGF) 저해제 시장 - 투여 경로별

• 개요

제9장 혈관내피세포성장인자(VEGF) 저해제 시장 - 용도별

• 개요

제10장 혈관내피세포성장인자(VEGF) 저해제 시장 - 지역별

• 서론
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동·아프리카

제11장 주요 벤더 분석 - 혈관내피세포성장인자(VEGF) 저해제 업계

• 경쟁 대시보드
• 기업 개요
  • Abbott(U.S.)
  • Sanofi(France)
  • AstraZeneca(U.K.)
  • Bristol-Myers Squibb Company(U.S.)
  • F. Hoffmann-La Roche Ltd(Switzerland)
  • Bayer AG(Germany)
  • Pfizer Inc(U.S.)
  • Teva Pharmaceutical Industries Ltd(Israel)
  • Novartis AG(Switzerland)
  • Genentech, Inc(U.S.)
  • Regeneron Pharmaceuticals Inc(U.S.)
  • Eisai Inc.(U.S.)

제12장 애널리스트의 견해

제13장 부록

KSA

영문 목차

영문목차

REPORT HIGHLIGHT

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market size was valued at USD 8,900.7 million in 2022, expanding at a CAGR of 9.1% from 2023 to 2030.

Initiating a network of signaling mechanisms that support endothelial cell growth, motility, and survival after the activation of the VEGF-receptor pathway is one of the main functions of VEGF, one of the main regulators of angiogenesis. At the moment, chemotherapy is frequently used in conjunction with angiogenesis inhibitors.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market- Market Dynamics

The vascular endothelial growth factor (VEGF) inhibitor market is anticipated to be driven by the rising frequency of cancer and macular degeneration illnesses. For instance, age-related macular degeneration will affect 8-7% of the world's population in August 2022, according to this systematic review and meta-analysis published by the National Library of Medicine, a US-based medical library, with the disease affecting 196 million people in 2020 and increasing to 288 million by 2040.Anti-vascular endothelial growth factor (anti-VEGF) medications slow the disease's progression and enhance vision. An inhibitor of the vascular endothelial growth factor (VEGF) inhibits and limits tumor growth in malignancies. As a result, during the course of the projection period, the market for VEGF inhibitors will rise due to the rising incidence of macular degeneration and cancer.

Additionally, for the treatment of individuals with significant tumor growth, more and more medications are getting approved. For instance, the new Eylea (aflibercept) injection pre-filled syringe that Bayer AG got clearance for from the European Medicines Agency (EMA) in April 2020 would give ophthalmologists a more effective and convenient way to deliver EYLEA across all approved indications. Compared to the current vial's intravitreal injection method, the pre-filled syringe is easier to prepare.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market- Segmentation Analysis:

The Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market is segmented based on Drugs Type, Route of Administration, Application, and Region.

Based on the application, the oncology segment is growing at the highest CAGR over the forecast period. The growth in the segment is attributed to the increasing prevalence of cancer across the globe. These inhibitors are used in the treatment of cancer such as. As per the World Cancer research Fund International, in 2020, there will be 18.1 million new cases of cancer worldwide. 9.3 million Of these instances involved men, while 8.8 million involved women.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market- Geographical Insights

North America is expected to dominate the market during the forecast period. The regional growth is owing to the presence of robust healthcare infrastructure. Moreover, the increasing prevalence of the cancer is another important factor that penetrate the market expansion. For instance, according to the American Cancer Society, in the United States, there are anticipated to be 1,918,030 new cancer cases and 609,360 cancer deaths in 2022, with lung cancer as the primary cause of death accounting for about 350 of those fatalities daily. On the other hand, the Asia Pacific region garner a significant market share in 2022 owing to the increasing incidence of cancer especially in the country like India, China and Others. In addition, the increasing cases related to the eye disease is also fuel the market expansion.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market- Recent Development:

In February 2022, Angiogenesis, Exudation and Degeneration is where Genentech, a part of the Roche Group, will present new two-year data from its Phase III studies of the drugs VabysmoTM (faricimab-svoa) and SusvimoTM (ranibizumab injection) 100 mg/mL for intravitreal administration via ocular implant.

Key features of the study:

This proposed research study on the Vascular Endothelial Growth Factor (VEGF) Inhibitors market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year

The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Vascular Endothelial Growth Factor (VEGF) Inhibitors market

The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Vascular Endothelial Growth Factor (VEGF) Inhibitors market

Impact of COVID-19 on Vascular Endothelial Growth Factor (VEGF) Inhibitors market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Vascular Endothelial Growth Factor (VEGF) Inhibitors market post-COVID will also be covered.

In order to give the users of this report a comprehensive view on the Vascular Endothelial Growth Factor (VEGF) Inhibitors market, we have also included competitive landscape and key innovator analysis for the Vascular Endothelial Growth Factor (VEGF) Inhibitors market.

The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.

The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Vascular Endothelial Growth Factor (VEGF) Inhibitors market.

In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.

The global Vascular Endothelial Growth Factor (VEGF) Inhibitors market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET KEY PLAYERS

Abbott (U.S.)

Sanofi (France)

AstraZeneca (U.K.)

Bristol-Myers Squibb Company (U.S.)

F. Hoffmann-La Roche Ltd (Switzerland)

Bayer AG (Germany)

Pfizer Inc (U.S.)

Teva Pharmaceutical Industries Ltd (Israel)

Novartis AG (Switzerland)

Genentech, Inc (U.S.)

Regeneron Pharmaceuticals Inc (U.S.)

Eisai Inc. (U.S.)

Merck & Co., Inc. (U.S.)

Exelixis, Inc. (U.S.).

GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET, BY DRUGS TYPE

Avastin

Tecentriq

Cometriq

Eylea

Others

GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION

Oral

Injectable

Others

GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET, BY APPLICATION

Oncology

Ophthalmology

Others

GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Russia

Netherlands

Sweden

Poland

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Australia

Thailand

Indonesia

Philippines

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Colombia

Rest of LATAM

The Middle East and Africa

Saudi Arabia

United Arab Emirates

Israel

Turkey

Algeria

Egypt

Rest of MEA

TABLE OF CONTENT

1. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Overview

• 1.1. Study Scope

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Snippet by Drugs Type
  • 2.1.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Snippet by Route of Administration
  • 2.1.3. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Snippet by Application
  • 2.1.4. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Snippet by Country
  • 2.1.5. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Snippet by Region
• 2.2. Competitive Insights

3. Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Market Trends

• 3.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Opportunities
• 3.4. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Future Trends

4. Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Landscape

• 6.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market - By Drugs Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drugs Type, 2022 & 2030 (%)
  • 7.1.2. Avastin
  • 7.1.3. Tecentriq
  • 7.1.4. Cometriq
  • 7.1.5. Eylea
  • 7.1.6. Others

8. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market - By Route of Administration

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
  • 8.1.2. Oral
  • 8.1.3. Injectable
  • 8.1.4. Others

9. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market - By Application

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
  • 9.1.2. Oncology
  • 9.1.3. Ophthalmology
  • 9.1.4. Others

10. Vascular Endothelial Growth Factor (VEGF) Inhibitors Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drugs Type, 2018 - 2030 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Abbott (U.S.)
  • 11.2.2. Sanofi (France)
  • 11.2.3. AstraZeneca (U.K.)
  • 11.2.4. Bristol-Myers Squibb Company (U.S.)
  • 11.2.5. F. Hoffmann-La Roche Ltd (Switzerland)
  • 11.2.6. Bayer AG (Germany)
  • 11.2.7. Pfizer Inc (U.S.)
  • 11.2.8. Teva Pharmaceutical Industries Ltd (Israel)
  • 11.2.9. Novartis AG (Switzerland)
  • 11.2.10. Genentech, Inc (U.S.)
  • 11.2.11. Regeneron Pharmaceuticals Inc (U.S.)
  • 11.2.12. Eisai Inc. (U.S.)

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us

관련자료